Clinical Trial Update: MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

The Phase 2/3 trial of MM-302 plus trastuzumab versus chemotherapy plus trastuzumab for HER2-positive locally advanced/metastatic breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MM-302 (liposomal doxorubicin (HER2-targeted))
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Merrimack Pharmaceuticals | Conditions: Breast Cancer, HER2 Positive Breast Cancer | Phase 2, Phase 3 | Status: TERMINATED